



Final Appraisal Recommendation

Advice No: 3715 – November 2015

Tinzaparin sodium (innohep[®] Syringe) 20,000 units/ml solution for injection

Limited submission by LEO Pharma

Recommendation of AWMSG

Tinzaparin sodium (innohep[®] Syringe) is recommended as an option for use within NHS Wales for the extended treatment of symptomatic venous thromboembolism and prevention of its recurrence in adult patients with solid tumours.

Additional note(s):

- This advice may be considered in conjunction with AWMSG recommendations on the prescribing of low molecular weight heparin in Wales.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2369), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by the Minister for Health and Social Services and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 3715: tinzaparin sodium (innohep[®] Syringe) 20,000 units/ml solution for injection. November 2015.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.